A Phase 3, Randomized, Double-Blind, Placebo - and Active - Comparator - Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma
Study of V940 Plus Pembrolizumab in Patients With High-Risk Melanoma
Sponsor: Merck
Enrolling: Male and Female Patients
IRB Number: AAAU7433
U.S. Govt. ID: NCT05933577
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare V940 plus pembro given after surgery to a placebo plus pembro given after surgery and to study how effective the study drug is. A placebo looks like a study drug, but it has no active ingredients. V940 has not yet been approved by the Food and Drug Administration (FDA). Pembrolizumab is FDA approved but it has not been approved for use with V940.
Benjamin Izar, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with high-risk melanoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator